Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)

Trial Profile

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cangrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Myocardial infarction; Stent thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CHAMPION; CHAMPION-PHOENIX; PHOENIX
  • Sponsors The Medicines Company
  • Most Recent Events

    • 25 Jan 2022 According to Chiesi Farmaceutici media release, results of post hoc analysis of this trial published in Circulation: Cardiovascular Interventions, a journal of the American Heart Association,
    • 25 Jan 2022 Results of post hoc analysis of this trial published in the Chiesi Farmaceutici Media Release
    • 29 Jun 2019 Results evaluating the efficacy and safety of cangrelor compared with clopidogrel among patients in the CHAMPION PHOENIX trial published in the Clinical Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top